NCM
AVTX icon

Nantahala Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Nantahala Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.4M Hold
1,235,000
– – 0.68% 41
2025
Q4 		$22.4M Hold
1,235,000
– – 0.74% 30
2025
Q3 		$15.7M Buy
1,235,000
+240,000
+24% +$2.06M 0.55% 43
2025
Q2 		$4.97M Buy
995,000
+95,000
+11% +$444K 0.19% 92
2025
Q1 		$7.21M Buy
+900,000
New +$6.82M 0.29% 55
2023
Q3 		– Sell
-2,318
Closed -$198K – 135
2023
Q2 		$198K Sell
2,318
-1,052
-31% -$708K 0.02% 112
2023
Q1 		$1.42M Buy
3,370
+1,117
+50% +$880K 0.11% 86
2022
Q4 		$2.73M Sell
2,253
-30
-1% -$39.1K 0.18% 69
2022
Q3 		$1.82M Sell
2,283
-47
-2% -$51K 0.12% 76
2022
Q2 		$3.35M Sell
2,330
-48
-2% -$64.2K 0.17% 69
2022
Q1 		$4.8M Sell
2,378
-103
-4% -$259K 0.21% 65
2021
Q4 		$12.1M Buy
2,481
+67
+3% +$402K 0.43% 47
2021
Q3 		$15.2M Buy
2,414
+218
+10% +$1.77M 0.48% 50
2021
Q2 		$20.7M Sell
2,196
-461
-17% -$3.86M 0.59% 40
2021
Q1 		$23.1M Buy
2,657
+493
+23% +$4.66M 0.68% 37
2020
Q4 		$16.5M Buy
2,164
+153
+8% +$1.06M 0.51% 47
2020
Q3 		$13.2M Buy
2,011
+38
+2% +$286K 0.4% 56
2020
Q2 		$14.8M Buy
+1,973
New +$14.3M 0.45% 47

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Nantahala Capital Management's AVTX Position: Q1 2026 in Review

Nantahala Capital Management held its Avalo Therapeutics (AVTX) position steady in Q1 2026 at 1,235,000 shares worth $18.4M. The position accounts for 0.68% of the portfolio, ranked #41.

Nantahala Capital Management first reported a position in AVTX in Q2 2020 and has held it in 18 quarters since. The position peaked at $23.1M in Q1 2021. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Nantahala Capital Management held 1,235,000 shares of Avalo Therapeutics worth $18.4M as of Q1 2026.
  • Nantahala Capital Management left its Avalo Therapeutics share count unchanged in Q1 2026.
  • Avalo Therapeutics made up 0.68% of Nantahala Capital Management's portfolio in Q1 2026, its #41 holding.
  • Nantahala Capital Management first reported a position in Avalo Therapeutics in Q2 2020 and has held it in 18 quarters since.
  • Nantahala Capital Management's Avalo Therapeutics position peaked at $23.1M in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.